UMCC 9901: Phase II Study of Tailored-Dose Docetaxel + Trastuzumab in Her-2 Positive Metastatic Breast Cancer

This study has been completed.

Study NCT00146042 Information provided by University of Michigan Cancer Center

First Received: September 1, 2005 Last Updated: February 5, 2012 History of Changes

No Study Results Posted on ClinicalTrials.gov for this Study

Study Status:	This study has been completed.
Study Completion Date:	March 2005
Primary Completion Date:	March 2004 (Final data collection date for primary outcome measure)